JP2022515369A5 - - Google Patents

Info

Publication number
JP2022515369A5
JP2022515369A5 JP2021534284A JP2021534284A JP2022515369A5 JP 2022515369 A5 JP2022515369 A5 JP 2022515369A5 JP 2021534284 A JP2021534284 A JP 2021534284A JP 2021534284 A JP2021534284 A JP 2021534284A JP 2022515369 A5 JP2022515369 A5 JP 2022515369A5
Authority
JP
Japan
Prior art keywords
compound
ppm
pharmaceutically acceptable
acceptable salt
groups
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021534284A
Other languages
English (en)
Japanese (ja)
Other versions
JP7573528B2 (ja
JP2022515369A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/066746 external-priority patent/WO2020131807A1/en
Publication of JP2022515369A publication Critical patent/JP2022515369A/ja
Publication of JP2022515369A5 publication Critical patent/JP2022515369A5/ja
Application granted granted Critical
Publication of JP7573528B2 publication Critical patent/JP7573528B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021534284A 2018-12-17 2019-12-17 Apol1の阻害剤及びその使用方法 Active JP7573528B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862780667P 2018-12-17 2018-12-17
US62/780,667 2018-12-17
PCT/US2019/066746 WO2020131807A1 (en) 2018-12-17 2019-12-17 Inhibitors of apol1 and methods of using same

Publications (3)

Publication Number Publication Date
JP2022515369A JP2022515369A (ja) 2022-02-18
JP2022515369A5 true JP2022515369A5 (cg-RX-API-DMAC7.html) 2022-12-23
JP7573528B2 JP7573528B2 (ja) 2024-10-25

Family

ID=69182627

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021534284A Active JP7573528B2 (ja) 2018-12-17 2019-12-17 Apol1の阻害剤及びその使用方法

Country Status (35)

Country Link
US (3) US11618746B2 (cg-RX-API-DMAC7.html)
EP (2) EP4782443A1 (cg-RX-API-DMAC7.html)
JP (1) JP7573528B2 (cg-RX-API-DMAC7.html)
KR (2) KR102912203B1 (cg-RX-API-DMAC7.html)
CN (1) CN113453760B (cg-RX-API-DMAC7.html)
AR (1) AR116913A1 (cg-RX-API-DMAC7.html)
AU (1) AU2019405477B2 (cg-RX-API-DMAC7.html)
CA (1) CA3121910A1 (cg-RX-API-DMAC7.html)
CL (1) CL2021001561A1 (cg-RX-API-DMAC7.html)
CO (1) CO2021009053A2 (cg-RX-API-DMAC7.html)
CR (1) CR20210383A (cg-RX-API-DMAC7.html)
DK (1) DK3897833T3 (cg-RX-API-DMAC7.html)
DO (1) DOP2021000116A (cg-RX-API-DMAC7.html)
EC (1) ECSP21052184A (cg-RX-API-DMAC7.html)
ES (1) ES3067546T3 (cg-RX-API-DMAC7.html)
FI (1) FI3897833T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20260487T1 (cg-RX-API-DMAC7.html)
IL (2) IL319575A (cg-RX-API-DMAC7.html)
JO (3) JOP20210131A1 (cg-RX-API-DMAC7.html)
LT (1) LT3897833T (cg-RX-API-DMAC7.html)
MA (1) MA54538B1 (cg-RX-API-DMAC7.html)
MD (1) MD3897833T2 (cg-RX-API-DMAC7.html)
MX (1) MX2021007152A (cg-RX-API-DMAC7.html)
PE (1) PE20212302A1 (cg-RX-API-DMAC7.html)
PL (1) PL3897833T3 (cg-RX-API-DMAC7.html)
PT (1) PT3897833T (cg-RX-API-DMAC7.html)
RS (1) RS68055B1 (cg-RX-API-DMAC7.html)
SA (1) SA521422270B1 (cg-RX-API-DMAC7.html)
SG (1) SG11202105769XA (cg-RX-API-DMAC7.html)
SI (1) SI3897833T1 (cg-RX-API-DMAC7.html)
SM (1) SMT202600169T1 (cg-RX-API-DMAC7.html)
TW (1) TWI848031B (cg-RX-API-DMAC7.html)
UA (1) UA128375C2 (cg-RX-API-DMAC7.html)
UY (1) UY38514A (cg-RX-API-DMAC7.html)
WO (1) WO2020131807A1 (cg-RX-API-DMAC7.html)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT3897833T (lt) * 2018-12-17 2026-04-27 Vertex Pharmaceuticals Incorporated Apol1 inhibitoriai ir jų panaudojimo būdai
EP4097083A1 (en) * 2020-01-29 2022-12-07 Vertex Pharmaceuticals Incorporated Inhibitors of apol1 and methods of using same
US20210246121A1 (en) * 2020-02-04 2021-08-12 Vertex Pharmaceuticals Incorporated Solid forms of apol1 inhibitor and methods of using same
EP4114385A1 (en) 2020-03-06 2023-01-11 Vertex Pharmaceuticals Incorporated Methods of treating apol-1 dependent focal segmental glomerulosclerosis
EP4146633A4 (en) 2020-05-07 2024-09-25 Rambam Med-Tech Ltd. COMPOSITION FOR USE IN THE TREATMENT OF A DISEASE ASSOCIATED WITH APOL1
CN115867543A (zh) * 2020-06-12 2023-03-28 弗特克斯药品有限公司 Apol1抑制剂的固体形式及其使用方法
JP2023530271A (ja) * 2020-06-12 2023-07-14 バーテックス ファーマシューティカルズ インコーポレイテッド Apol1の阻害剤及びこれを使用する方法
US20230014907A1 (en) * 2020-06-12 2023-01-19 Vertex Pharmaceuticals Incorporated Inhibitors of apol1 and methods of using same
BR112023003423A2 (pt) 2020-08-26 2023-03-21 Vertex Pharma Inibidores de apol1 e métodos de uso destes
CA3179178A1 (en) 2021-02-19 2022-08-25 Maze Therapeutics, Inc. Apol1 inhibitors and methods of use
KR20240051990A (ko) * 2021-08-26 2024-04-22 버텍스 파마슈티칼스 인코포레이티드 스피로트리시클릭 apol1 억제제의 고형분 형태 및 이의 사용 방법
AU2022401847A1 (en) * 2021-11-30 2024-06-06 Vertex Pharmaceuticals Incorporated Spirocyclic inhibitors of apol1 and methods of using same
US12612379B2 (en) 2021-11-30 2026-04-28 Vertex Pharmaceuticals Incorporated Inhibitors of APOL1 and methods of using same
MX2024008868A (es) * 2022-01-18 2024-09-23 Maze Therapeutics Inc Inhibidores de la apolipoproteína l1 (apol1) y métodos de uso.
CN119343353A (zh) * 2022-02-08 2025-01-21 弗特克斯药品有限公司 作为APOL1抑制剂的2-甲基-4',5'-二氢螺[哌啶-4,7'-噻吩并[2,3-c]吡喃]衍生物和其使用方法
WO2023194895A1 (en) 2022-04-06 2023-10-12 Glaxosmithkline Intellectual Property Development Limited Pyrrol derivatives as inhibitors of apolipoprotein l-1
US20260055083A1 (en) * 2022-08-19 2026-02-26 Maze Therapeutics, Inc. Apol1 inhibitors and methods of use
WO2025006262A1 (en) * 2023-06-29 2025-01-02 Omniab, Inc. Tetracyclic compounds containing a fused indole for treating apol1-mediated chronic kidney disease
GB202401326D0 (en) * 2024-02-01 2024-03-20 Podium Bio Ltd Novel compounds
KR20250122547A (ko) 2024-02-05 2025-08-14 서주사이언티픽 주식회사 AIoT 기반 방사성 동위원소 관리 시스템
TW202613098A (zh) * 2024-07-09 2026-04-01 大陸商上海旭成醫藥科技有限公司 一種APOLs抑制劑

Family Cites Families (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4039676A (en) 1975-06-23 1977-08-02 Ciba-Geigy Corporation 2-piperidinoalkyl-1,4-benzodioxans
CA2262569A1 (en) 1996-08-09 1998-02-19 Norihito Ohi Benzopiperidine derivatives
EP0924209B1 (en) 1997-12-19 2003-05-02 Eli Lilly And Company Hypoglycemic imidazoline compounds
GB9905010D0 (en) 1999-03-04 1999-04-28 Merck Sharp & Dohme Therapeutic agents
WO2001017965A2 (en) 1999-09-07 2001-03-15 Syngenta Participations Ag Cyanopiperidines as pesticides
FR2801585B1 (fr) 1999-11-25 2002-02-15 Fournier Ind & Sante Nouveaux antagonistes des recepteurs de l'ii-8
GB0003397D0 (en) 2000-02-14 2000-04-05 Merck Sharp & Dohme Therapeutic agents
WO2002028831A1 (en) 2000-10-02 2002-04-11 Merck & Co., Inc. Inhibitors of prenyl-protein transferase
FR2824826B1 (fr) 2001-05-17 2003-11-07 Fournier Lab Sa Nouveaux derives de 5-cyano-1h-indole antagonistes des recepteurs de l'interleukine-8
FR2824827B1 (fr) 2001-05-17 2004-02-13 Fournier Lab Sa Nouveaux derives de 5-phenyl-1h-indole antagoniste des recepteurs de l'interleukine-8
KR20050044450A (ko) 2001-11-14 2005-05-12 테바 파마슈티컬 인더스트리즈 리미티드 로사르탄 칼륨의 무정형 및 결정형 형태 및 이의 제조 방법
WO2003104180A1 (en) * 2002-06-05 2003-12-18 Natco Pharma Limited Process for the preparation of 4-(4-fluorobenzoyl) butyric acid
WO2004058717A1 (en) 2002-12-20 2004-07-15 X-Ceptor Therapeutics, Inc. Isoquinolinone derivatives and their use as therapeutic agents
AU2004268919A1 (en) 2003-09-03 2005-03-10 Galapagos Nv Novel 4-piperidinecarboxamide and the use thereof for the preparation of medicaments against 5-HT2A receptor-related disorders
WO2005092854A1 (en) 2004-03-03 2005-10-06 Eli Lilly And Company Bicyclic substituted indole-derivative steroid hormone nuclear receptor modulators
AR048523A1 (es) 2004-04-07 2006-05-03 Kalypsys Inc Compuestos con estructura de aril sulfonamida y sulfonilo como moduladores de ppar y metodos para tratar trastornos metabolicos
WO2007061763A2 (en) 2005-11-22 2007-05-31 Merck & Co., Inc. Indole orexin receptor antagonists
US8222288B2 (en) 2006-08-30 2012-07-17 The Regents Of The University Of Michigan Small molecule inhibitors of MDM2 and the uses thereof
EP2086935A1 (de) 2006-10-16 2009-08-12 Grünenthal GmbH Substituierte sulfonamid-derivate als bradykinin 1 rezeptor modulatoren
CN101563324A (zh) 2006-12-22 2009-10-21 弗·哈夫曼-拉罗切有限公司 螺-哌啶衍生物
PT2118074E (pt) * 2007-02-01 2014-03-20 Resverlogix Corp Compostos para a prevenção e tratamento de doenças cardiovasculares
EP2020414A1 (en) 2007-06-20 2009-02-04 Laboratorios del Dr. Esteve S.A. spiro[piperidine-4,4'-thieno[3,2-c]pyran] derivatives and related compounds as inhibitors of the sigma receptor for the treatment of psychosis
EP2178870B1 (en) 2007-08-17 2018-09-19 LG Chem, Ltd. Indole and indazole compounds as an inhibitor of cellular necrosis
KR101605061B1 (ko) 2009-05-29 2016-03-21 라퀄리아 파마 인코포레이티드 칼슘 또는 나트륨 채널 차단제로서의 아릴 치환된 카복사미드 유도체
UA107943C2 (xx) 2009-11-16 2015-03-10 Lilly Co Eli Сполуки спіропіперидину як антагоністи рецептора orl-1
PL2501704T3 (pl) 2009-11-16 2014-02-28 Lilly Co Eli Spiropiperydynowe związki jako antagoniści receptora ORL-1
WO2012025155A1 (en) 2010-08-26 2012-03-01 Novartis Ag Hydroxamate-based inhibitors of deacetylases
BR102012024778A2 (pt) 2012-09-28 2014-08-19 Cristalia Prod Quimicos Farm Compostos heteroaromáticos; processo para preparar os compostos, composições farmacêuticas, usos e método de tratamento para as dores aguda e crônica
US10130632B2 (en) 2012-11-27 2018-11-20 Beth Israel Deaconess Medical Center, Inc. Methods for treating renal disease
US9850203B2 (en) * 2013-09-26 2017-12-26 Pharmakea, Inc. Autotaxin inhibitor compounds
ES2895490T3 (es) 2014-03-27 2022-02-21 Acad Medisch Ct Iminoazúcares N-(5-(bifen-4-ilmetiloxi)pentil)-sustituidos como inhibidores de glucosilceramida sintasa
WO2016029310A1 (en) 2014-08-27 2016-03-03 The Governing Council Of The University Of Toronto Cannabinoid type 1 receptor modulators
BR112017007178A2 (pt) 2014-10-08 2017-12-19 Ass Francaise Contre Les Myopathies compostos de aminopiridina úteis como inibidores de prenilação de proteína
JP2017535545A (ja) 2014-11-21 2017-11-30 ラボラトリオス・デル・デエレ・エステベ・エセ・ア 疼痛に対する多様な活性を有するスピロ−イソキノリン−1,4’−ピペリジン化合物
HRP20210472T1 (hr) 2015-08-27 2021-05-14 Pfizer Inc. Biciklički kondenzirani heteroarilni ili arilni spojevi kao modulatori irak4
CN108884096B (zh) 2016-02-08 2022-03-22 豪夫迈·罗氏有限公司 作为ddr1抑制剂的螺二氢吲哚酮
EP3787669A4 (en) 2018-04-30 2022-03-30 The Trustees of Indiana University COMPOUNDS FOR MODULATION OF LEVELS OF DDAH AND ADMA AND METHODS OF USE THEM TO TREAT DISEASES
CN118127019A (zh) 2018-05-22 2024-06-04 Ionis制药公司 Apol1表达的调节剂
LT3897833T (lt) 2018-12-17 2026-04-27 Vertex Pharmaceuticals Incorporated Apol1 inhibitoriai ir jų panaudojimo būdai
US20220144838A1 (en) 2019-03-13 2022-05-12 Nanjing Immunophage Biotech Co., Ltd. Compounds as Inhibitors of Macrophage Migration Inhibitory Factor
US12698266B2 (en) 2019-12-19 2026-08-04 Casma Therapeutics, Inc. TRPML modulators
EP4097083A1 (en) 2020-01-29 2022-12-07 Vertex Pharmaceuticals Incorporated Inhibitors of apol1 and methods of using same
US20210246121A1 (en) * 2020-02-04 2021-08-12 Vertex Pharmaceuticals Incorporated Solid forms of apol1 inhibitor and methods of using same
EP4114385A1 (en) * 2020-03-06 2023-01-11 Vertex Pharmaceuticals Incorporated Methods of treating apol-1 dependent focal segmental glomerulosclerosis
CA3171950A1 (en) 2020-04-22 2021-10-28 David William Sheppard Collagen 1 translation inhibitors and methods of use thereof
HUP2200468A1 (hu) 2020-04-29 2023-03-28 X Chem Zrt IAP antagonisták és gyógyászati alkalmazásuk
EP4146633A4 (en) 2020-05-07 2024-09-25 Rambam Med-Tech Ltd. COMPOSITION FOR USE IN THE TREATMENT OF A DISEASE ASSOCIATED WITH APOL1
JP2023530271A (ja) 2020-06-12 2023-07-14 バーテックス ファーマシューティカルズ インコーポレイテッド Apol1の阻害剤及びこれを使用する方法
CN115867543A (zh) 2020-06-12 2023-03-28 弗特克斯药品有限公司 Apol1抑制剂的固体形式及其使用方法
US20230014907A1 (en) 2020-06-12 2023-01-19 Vertex Pharmaceuticals Incorporated Inhibitors of apol1 and methods of using same
BR112023003423A2 (pt) 2020-08-26 2023-03-21 Vertex Pharma Inibidores de apol1 e métodos de uso destes
KR20240051990A (ko) 2021-08-26 2024-04-22 버텍스 파마슈티칼스 인코포레이티드 스피로트리시클릭 apol1 억제제의 고형분 형태 및 이의 사용 방법
US12612379B2 (en) 2021-11-30 2026-04-28 Vertex Pharmaceuticals Incorporated Inhibitors of APOL1 and methods of using same
AU2022401847A1 (en) 2021-11-30 2024-06-06 Vertex Pharmaceuticals Incorporated Spirocyclic inhibitors of apol1 and methods of using same
CN119343353A (zh) 2022-02-08 2025-01-21 弗特克斯药品有限公司 作为APOL1抑制剂的2-甲基-4',5'-二氢螺[哌啶-4,7'-噻吩并[2,3-c]吡喃]衍生物和其使用方法
WO2023154314A1 (en) 2022-02-08 2023-08-17 Vertex Pharmaceuticals Incorporated Spiro piperidine derivatives as inhibitors of apol1 and methods of using same
EP4476199A1 (en) 2022-02-08 2024-12-18 Vertex Pharmaceuticals Incorporated 2-methyl-4-phenylpiperidin-4-ol derivatives as inhibitors of apol1 and methods of using same
EP4476228A1 (en) 2022-02-08 2024-12-18 Vertex Pharmaceuticals Incorporated 4',5'-dihydrospiro[piperidine-4,7'-thieno[2,3-c]pyran] derivatives as inhibitors of apol1 and methods of using same

Similar Documents

Publication Publication Date Title
TWI844568B (zh) 抑制shp2活性化合物之製造方法、及由酸加成產生之產物
IL283592B1 (en) APOL1 inhibitors and methods of using them
JP7579253B2 (ja) 甲状腺ホルモン受容体ベータアゴニスト化合物
US11248012B2 (en) Phospholipidation of imidazoquinolines and oxoadenines
JP2021523225A5 (cg-RX-API-DMAC7.html)
RU2017121906A (ru) Конъюгаты цистеамина и жирной кислоты и их применение в качестве активаторов аутофагии
KR20110059841A (ko) 강력한 hcv 억제제인 2-티아졸릴-4-퀴놀리닐-옥시 유도체의 결정 형태
ES2699884T3 (es) Nuevo compuesto cristalino de arilalquilamina y método para producir el mismo
RU2684402C2 (ru) Новый тип производного цитидина и его применение
WO1985001727A1 (en) Novel synthetic methods for non-ionic radiographic contrast media
WO2013006734A1 (en) Substituted 4-phenoxyphenol analogs as modulators of proliferating cell nuclear antigen activity
JPH02104588A (ja) 5員‐又は6員‐環を有する巨大環状ポリアザ‐化合物、その製法及びこれを含有するnmr‐、x線‐、放射線‐診断用及び放射能‐及び照射線‐治療用薬剤及びこの薬剤の製法
KR20200108828A (ko) 발베나진의 고상 형태
WO2022135591A1 (zh) 芳基或杂芳基并吡啶酮或嘧啶酮类衍生物及其制备方法和应用
ES2671608T3 (es) Formas sólidas de 3-(4-nitro-1-oxoisoindolin-2-il)piperidina-2,6-diona
ES2675398T3 (es) Formas de sal de meglumina del ácido 2-((1R,4R)-4-(4-(5-(benzoxazol-2-ilamino)piridin-2-il)fenil)ciclohexil)-acético, y su uso como inhibidores de DGAT1
CN101365461A (zh) 舒林酸(sulindac)衍生物、其用途和其制备
US8236850B2 (en) Dimeric derivatives of artemisinin and application in anticancer therapy
EP3525795B1 (en) Phenothiazine derivatives and methods of use thereof
JP6271091B2 (ja) 新規シチジン誘導体二量体およびその応用
WO2005123676A1 (en) Bi- or tetra-guanidino-biphenyl compounds as small molecule carriers
EP4359391A1 (en) Triazine derivatives for the treatment of tumours and neurodegenerative disorders
JP2007505071A (ja) 結晶多形性ヌクレオシド化合物
HK1126147A (en) Derivatives of sulindac, use thereof and preparation thereof